BTIG Remains a Buy on Akoya Biosciences (AKYA)

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Akoya Biosciences (AKYAResearch Report), with a price target of $18.00. The company’s shares closed last Tuesday at $13.63.

According to, Massaro is a 3-star analyst with an average return of 1.4% and a 44.9% success rate. Massaro covers the Healthcare sector, focusing on stocks such as MDxHealth S.A. Sponsored ADR, Adaptive Biotechnologies, and Ginkgo Bioworks Holdings.

Akoya Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $16.67.

See the top stocks recommended by analysts >>

Based on Akoya Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $16.89 million and GAAP net loss of $16.4 million. In comparison, last year the company earned revenue of $12.21 million and had a GAAP net loss of $8.08 million.

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AKYA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akoya Biosciences Inc is an an innovative life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. It offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.

Read More on AKYA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More